Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.
Journal
The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
21
11
2022
revised:
09
12
2022
accepted:
14
12
2022
medline:
8
5
2023
pubmed:
25
2
2023
entrez:
24
2
2023
Statut:
ppublish
Résumé
Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of remdesivir compared with placebo or usual care in these patients, and whether treatment effects differed between prespecified patient subgroups. For this systematic review and meta-analysis, we searched PubMed, Embase, the Cochrane COVID-19 trial registry, ClinicalTrials.gov, the International Clinical Trials Registry Platform, and preprint servers from Jan 1, 2020, until April 11, 2022, for RCTs of remdesivir in adult patients hospitalised with COVID-19, and contacted the authors of eligible trials to request individual patient data. The primary outcome was all-cause mortality at day 28 after randomisation. We used multivariable hierarchical regression-adjusting for respiratory support, age, and enrollment period-to investigate effect modifiers. This study was registered with PROSPERO, CRD42021257134. Our search identified 857 records, yielding nine RCTs eligible for inclusion. Of these nine eligible RCTs, individual data were provided for eight, covering 10 480 patients hospitalised with COVID-19 (99% of such patients included in such RCTs worldwide) recruited between Feb 6, 2020, and April 1, 2021. Within 28 days of randomisation, 662 (12·5%) of 5317 patients assigned to remdesivir and 706 (14·1%) of 5005 patients assigned to no remdesivir died (adjusted odds ratio [aOR] 0·88, 95% CI 0·78-1·00, p=0·045). We found evidence for a credible subgroup effect according to respiratory support at baseline (p This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir. The effect size of remdesivir in patients with more respiratory support or acquired immunity and the cost-effectiveness of remdesivir remain to be further elucidated. EU-RESPONSE.
Sections du résumé
BACKGROUND
Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of remdesivir compared with placebo or usual care in these patients, and whether treatment effects differed between prespecified patient subgroups.
METHODS
For this systematic review and meta-analysis, we searched PubMed, Embase, the Cochrane COVID-19 trial registry, ClinicalTrials.gov, the International Clinical Trials Registry Platform, and preprint servers from Jan 1, 2020, until April 11, 2022, for RCTs of remdesivir in adult patients hospitalised with COVID-19, and contacted the authors of eligible trials to request individual patient data. The primary outcome was all-cause mortality at day 28 after randomisation. We used multivariable hierarchical regression-adjusting for respiratory support, age, and enrollment period-to investigate effect modifiers. This study was registered with PROSPERO, CRD42021257134.
FINDINGS
Our search identified 857 records, yielding nine RCTs eligible for inclusion. Of these nine eligible RCTs, individual data were provided for eight, covering 10 480 patients hospitalised with COVID-19 (99% of such patients included in such RCTs worldwide) recruited between Feb 6, 2020, and April 1, 2021. Within 28 days of randomisation, 662 (12·5%) of 5317 patients assigned to remdesivir and 706 (14·1%) of 5005 patients assigned to no remdesivir died (adjusted odds ratio [aOR] 0·88, 95% CI 0·78-1·00, p=0·045). We found evidence for a credible subgroup effect according to respiratory support at baseline (p
INTERPRETATION
This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir. The effect size of remdesivir in patients with more respiratory support or acquired immunity and the cost-effectiveness of remdesivir remain to be further elucidated.
FUNDING
EU-RESPONSE.
Identifiants
pubmed: 36828006
pii: S2213-2600(22)00528-8
doi: 10.1016/S2213-2600(22)00528-8
pmc: PMC10156140
mid: NIHMS1879268
pii:
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-464Subventions
Organisme : Intramural NIH HHS
ID : Z99 AI999999
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests DC reports an HIV grant from Janssen and personal fees from Gilead Sciences and Pfizer for lectures outside of the submitted work. MBr and BS report an unrestricted grant from Moderna for a study outside of the submitted work. TCL reports salary support from the Fonds de Recherche du Québec Santé. MH reports personal fees from Gilead Sciences and Pfizer for lectures outside of the submitted work, and congress and travel fees from Pfizer and Gilead Sciences. ICO reports funding from BerGenBio for a study outside of the submitted work. All other authors declare no competing interests.
Références
F1000Res. 2020 Oct 2;9:1193
pubmed: 33082937
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Nat Commun. 2022 Oct 18;13(1):6152
pubmed: 36257950
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Clin Trials. 2020 Oct;17(5):472-482
pubmed: 32674594
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Indian J Anaesth. 2021 Mar;65(Suppl 1):S41-S46
pubmed: 33814589
J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412
pubmed: 35233617
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
Ann Intern Med. 2021 Sep;174(9):1261-1269
pubmed: 34251903
N Engl J Med. 2022 Aug 4;387(5):468-470
pubmed: 35857646
J Clin Epidemiol. 2020 Feb;118:124-131
pubmed: 31711910
Stat Med. 2020 Aug 30;39(19):2536-2555
pubmed: 32394498
BMJ. 2008 May 3;336(7651):995-8
pubmed: 18456631
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Stat Med. 2017 Nov 10;36(25):3923-3934
pubmed: 28748567
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
Nat Med. 2020 Nov;26(11):1671-1672
pubmed: 32963376
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Crit Care Med. 2020 Nov;48(11):1622-1635
pubmed: 32804792
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Clin Microbiol Infect. 2020 Aug;26(8):988-998
pubmed: 32454187
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Clin Trials. 2005;2(3):209-17
pubmed: 16279144
Lancet Infect Dis. 2023 Jan;23(1):22-23
pubmed: 36410372
N Engl J Med. 2023 Jan 5;388(1):89-91
pubmed: 36476720
CMAJ. 2022 Feb 22;194(7):E242-E251
pubmed: 35045989
Lancet Infect Dis. 2022 Jun;22(6):764-765
pubmed: 35643099
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
PLoS Med. 2015 Jul 21;12(7):e1001855
pubmed: 26196287
Stat Med. 2004 Aug 30;23(16):2509-25
pubmed: 15287081
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Clin Microbiol Infect. 2022 Sep;28(9):1203-1210
pubmed: 35598856
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2022 May 21;399(10339):1941-1953
pubmed: 35512728
Lancet Infect Dis. 2022 Feb;22(2):209-221
pubmed: 34534511
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601